Balaxi Pharmaceuticals Limited (BALAXI.NS)
INR 66.96
(-1.18%)
INR 66.96
(-1.18%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 2.38 Billion | 3.36 Billion | 2.79 Billion | 2.31 Billion | 456.32 Million | 135.95 Million |
| Cost of Revenue | 1.32 Billion | 2.02 Billion | 1.95 Billion | 1.72 Billion | 335.76 Million | 104.69 Million |
| Gross Profit | 1.06 Billion | 1.34 Billion | 837.91 Million | 591.85 Million | 120.55 Million | 31.25 Million |
| Operating Expenses | 656.74 Million | 792.31 Million | 334.8 Million | 167.68 Million | 59.45 Million | 14.93 Million |
| Selling, General and Administrative Expenses | 656.74 Million | 485.25 Million | 141.62 Million | 6.8 Million | 2.25 Million | 1.49 Million |
| Research and Development Expenses | - | 0.17 | 0.19 | 0.19 | 0.19 | 0.18 |
| Other Expenses | - | 26.36 Million | 193.18 Million | 160.87 Million | 22.5 Million | 8.08 Million |
| Cost and Expenses | 1.94 Billion | 2.81 Billion | 2.29 Billion | 1.88 Billion | 395.22 Million | 119.63 Million |
| Operating Income | 467.3 Million | 574.22 Million | 546.63 Million | 443.84 Million | 82.33 Million | 16.31 Million |
| Interest Expense | 16.77 Million | 5 Million | 1.41 Million | 184 Thousand | 478 Thousand | - |
| Income Tax Expense | 44.02 Million | 109.59 Million | 68.64 Million | 61.91 Million | 27.69 Million | 4.73 Million |
| Earnings before Tax | 20.15 Million | 569.22 Million | 545.22 Million | 443.29 Million | 88.73 Million | 24.39 Million |
| Net Income | -23.87 Million | 459.62 Million | 476.57 Million | 381.37 Million | 61.03 Million | 19.65 Million |
| Earnings Per Share Basic | -0.46 | 9.16 | 9.53 | 7.63 | 1.62 | 1.29 |
| Earnings Per Share Diluted | -0.46 | 9.08 | 9.53 | 7.63 | 1.62 | 1.29 |
| Weighted Average Shares Outstanding | 51.47 Million | 50.61 Million | 50 Million | 50 Million | 37.6 Million | 15.2 Million |
| Weighted Average Shares Outstanding (Diluted) | 51.47 Million | 50.61 Million | 50 Million | 50 Million | 37.6 Million | 15.2 Million |
| Gross Margin | 0.44 | 0.40 | 0.30 | 0.26 | 0.26 | 0.23 |
| EBIT Margin | 0.19 | 0.18 | 0.20 | 0.19 | 0.19 | 0.18 |
| Profit Margin | -0.01 | 0.14 | 0.17 | 0.16 | 0.13 | 0.14 |
| EBITDA | 456.58 Million | 591.74 Million | 551.76 Million | 446.82 Million | 82.41 Million | 22.31 Million |
| Earnings Before Tax Margin | 0.20 | 0.17 | 0.20 | 0.19 | 0.18 | 0.12 |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 637.73 Million | 2.38 Billion | 580.47 Million | 607.85 Million | 547.2 Million | 659.55 Million |
| Cost of Revenue | 389.99 Million | 1.32 Billion | 301.61 Million | 303.6 Million | 291.2 Million | 403.13 Million |
| Gross Profit | 247.74 Million | 1.06 Billion | 278.86 Million | 304.24 Million | 256 Million | 256.42 Million |
| Operating Expenses | 197.39 Million | 658.83 Million | 174.81 Million | 172.45 Million | 154.96 Million | 170.87 Million |
| Selling, General and Administrative Expenses | 173.99 Million | - | 112.52 Million | 90.68 Million | 82.73 Million | 99.14 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | -173.99 Million | -658.83 Million | -174.81 Million | -1.32 Million | 2.79 Million | -10.08 Million |
| Cost and Expenses | 563.98 Million | 1.98 Billion | 476.42 Million | 476.06 Million | 446.17 Million | 574 Million |
| Operating Income | 73.74 Million | 403.08 Million | 104.04 Million | 130.46 Million | 103.83 Million | 75.46 Million |
| Interest Expense | 3.7 Million | 16.77 Million | 6.05 Million | 4.14 Million | 3.68 Million | 2.89 Million |
| Income Tax Expense | 8.94 Million | 44.02 Million | 5.59 Million | 6.79 Million | 12.32 Million | 19.3 Million |
| Earnings before Tax | 73.74 Million | 20.15 Million | 114.93 Million | 142.73 Million | 156.6 Million | -394.12 Million |
| Net Income | 64.8 Million | -23.86 Million | 109.33 Million | 135.93 Million | 144.28 Million | -413.43 Million |
| Earnings Per Share Basic | 1.17 | - | 2.08 | 2.66 | 2.82 | -8.10 |
| Earnings Per Share Diluted | 1.17 | - | 2.08 | 2.64 | 2.81 | -8.10 |
| Weighted Average Shares Outstanding | 55.38 Million | 51.47 Million | 52.66 Million | 51.41 Million | 51.31 Million | 51.05 Million |
| Weighted Average Shares Outstanding (Diluted) | 55.38 Million | 51.47 Million | 52.66 Million | 51.41 Million | 51.31 Million | 51.05 Million |
| Gross Margin | 0.39 | 0.44 | 0.48 | 0.50 | 0.47 | 0.39 |
| EBIT Margin | 0.12 | - | 0.19 | 0.22 | 0.20 | 0.12 |
| Profit Margin | 0.10 | -0.01 | 0.19 | 0.22 | 0.26 | -0.63 |
| EBITDA | 78.67 Million | - | 110.75 Million | 135.27 Million | 110.44 Million | 78.32 Million |
| Earnings Before Tax Margin | 0.12 | 0.17 | 0.18 | 0.21 | 0.19 | 0.11 |
MYG
CYRBY
002642
013120
TRN
LMG